Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. 2006

Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
Department of Clinical Pharmacology, Hirosaki University School of Medicine, Hirosaki University Hospital, Hirosaki, Japan. uno-hki@umin.ac.jp

A simple and sensitive column-switching high-performance liquid chromatographic method for the simultaneous determination of itraconazole (ITZ) and its active metabolite, hydroxyitraconazole (HIT) in human plasma is described. ITZ, HIT, and an internal standard, R051012, were extracted from 1 mL of alkalinized plasma sample using n-heptane-chloroform (60:40, vol/vol). The extract was injected onto column I (TSK precolumn BSA-ODS/S, 5 microm, 10 x 4.6 mm ID) for clean-up and column II (Develosil C8-5 column, 5 microm, 150 x 4.6 mm ID) for separation. The mobile phase consisted of phosphate buffer-acetonitrile (68:32 vol/vol, pH 6.0) for clean-up and phosphate buffer-acetonitrile (35:65 vol/vol, pH 6.0) for separation. The peaks were monitored with an ultraviolet detector set at a wavelength of 263 nm, and total time for chromatographic separation was about 24 minutes. The validated concentration ranges of this method were 3 to 500 ng/mL for ITZ and 3 to 1000 ng/mL for HIT. Mean recoveries were 59.7% for ITZ and 72.8% for HIT. Intraday and interday coefficients of variation were less than 4.6% and 5.0% for ITZ, and 4.6% and 4.9% for HIT at the different concentrations. The limit of quantification was 3 ng/mL for both ITZ and HIT. This method was suitable for therapeutic drug monitoring of ITZ and HIT, and was applied to pharmacokinetic studies in human volunteers.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002725 Chloroform A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity. Trichloromethane
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D006536 Heptanes Seven-carbon alkanes with the formula C7H16. Heptane,Isoheptane,Isoheptanes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
December 1994, Therapeutic drug monitoring,
Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
September 1989, Journal of chromatography,
Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
June 1997, Journal of chromatography. B, Biomedical sciences and applications,
Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
February 2000, Journal of chromatography. B, Biomedical sciences and applications,
Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
January 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
March 2000, Journal of chromatography. B, Biomedical sciences and applications,
Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
July 1992, Journal of pharmaceutical sciences,
Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
February 2001, Journal of chromatography. B, Biomedical sciences and applications,
Tsukasa Uno, and Mikiko Shimizu, and Kazunobu Sugawara, and Tomonori Tateishi
June 2007, Therapeutic drug monitoring,
Copied contents to your clipboard!